Neuronetics outlines $160M-$164M 2026 revenue outlook while targeting limited to no net cash utilization in H2 (NASDAQ:STIM)

Neuronetics Inc (STIM) reported Q3 2026 revenue of $42M, up 12.5% YoY, driven by Greenbrook's 20.1% growth. Gross margin expanded to 52.2%, and operating expenses decreased 12.6%, leading to positive adjusted EBITDA of $1.9M. NeuroStar revenue grew only 1.8% YoY, with session revenue declining. Cash balance decreased to $27.9M. Management expects full-year 2026 cash flow to be negative $10M to $12M.

Neuronetics reported Q3 revenue growth driven by record system sales, with capital and lease units making up over half of sales. The company expects lower treatment-session revenue as it shifts focus to larger customers. Neuronetics anticipates higher growth in 2027 and beyond. It also submitted a 510(k) application for an accelerated TMS protocol and cited a study showing treatment gaps do not reduce effectiveness.

Lyell Immunopharma (LYEL) rose 44% after securing $80M in financing and reporting positive clinical data. LivaNova (LIVN) gained 23% on strong Q3 results and raised guidance. UFP Technologies (UFPT) advanced 22% with 11.6% sales growth and improved profitability. Neuronetics (STIM) rose 21% as Q3 loss narrowed and EBITDA turned positive.

Neuronetics Inc. (STIM) reported Q3 2026 revenue of $42.0M, up 12.5% YoY, with positive operating income of $0.5M. Gross margin expanded to 52.2%, and adjusted EBITDA improved to $1.9M. The company treats 29.3M Americans with depression and related conditions, offering TMS and esketamine therapies. CEO Dan Reuvers attributed results to record NeuroStar system sales and clinic strength. Future growth includes psychedelic therapies pending FDA approval.

Neuronetics (STIM) reported a narrower Q3 net loss of $1.7M, down from $9.0M YoY, as revenue rose 12.5% to $42.0M. Greenbrook clinic revenue increased 20.1%. Gross margin improved to 52.2%, and operating expenses declined 13%. The company reaffirmed its 2026 revenue guidance of $160M-$164M and raised its gross margin outlook.

Neuronetics reported Q3 2026 revenue of $41.96M, up 12.5% YoY, with a net loss of $1.69M, improved from $9.05M. EPS loss was $0.02. Nine-month revenue rose 10% to $118.0M. Greenbrook clinics contributed 62% of Q3 revenue, growing 20%. NeuroStar revenue was $15.8M. Management expects Greenbrook growth and NeuroStar sales acceleration.